Company news

Pharvaris N.V. news in 2023

Pharvaris N.V.'s news releases, calls and decks from 2023, newest first.

View company

Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023

December 7, 2023

Pharvaris Announces Pricing of $300 Million Underwritten Offering of Ordinary Shares and Pre-funded Warrants

December 5, 2023

Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks

December 5, 2023

Pharvaris to Present at the GA²LEN UCARE Conference 2023

November 29, 2023

Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer

November 14, 2023

Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific Meeting

November 8, 2023

Pharvaris Reports Third Quarter 2023 Financial Results and Provides Business Update

November 1, 2023

Pharvaris To Present at the ACAAI 2023 Annual Scientific Meeting

October 29, 2023

Pharvaris To Present at the APAAACI 2023 International Conference

October 12, 2023

Pharvaris To Present at the CIIC Fall 2023 Conference

October 3, 2023

Pharvaris To Participate in the 2023 Cantor Global Healthcare Conference

September 18, 2023

Pharvaris To Present at the 18th German Allergy Congress

September 5, 2023

Pharvaris To Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

September 5, 2023

Pharvaris To Present at the 2023 HAEi Regional Conference EMEA

August 22, 2023

Pharvaris Reports Second Quarter 2023 Financial Results and Provides Business Update

August 6, 2023

Pharvaris Presents Clinical Data at the 2023 U.S. HAEA National Summit

July 20, 2023

Pharvaris Announces FDA Removal of Clinical Hold of Deucrictibant for the On-Demand Treatment of HAE

June 25, 2023

Pharvaris Announces $70 Million Private Placement Financing

June 19, 2023

Data of Deucrictibant for the On-Demand Treatment of HAE Attacks Presented at the EAACI Congress 2023

June 10, 2023

Pharvaris Reports First Quarter 2023 Financial Results and Provides Business Update

May 7, 2023

Deucrictibant Data Highlighted in Multiple Presentations at the C1-Inhibitor Deficiency and Angioedema Workshop

May 5, 2023

Pharvaris Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

April 4, 2023

Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks Highlighted at the 2023 HAEi Regional Conference APAC

March 17, 2023

Pharvaris to Present in Upcoming March Investor Conferences

March 1, 2023

Pharvaris to Highlight Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks at AAAAI Annual Meeting

February 23, 2023

Pharvaris to Present at SVB Securities Global Biopharma Conference

February 7, 2023

Pharvaris Provides Regulatory, Clinical, and Corporate Updates

January 8, 2023

Decks in 2023